TaiMed Biologics (TPEX: 4147) today announced that enrollment in the Phase 2b clinical trial of its long-acting HIV dual-antibody therapy, TMB-365/380, is progressing ahead of schedule. The study is advancing smoothly, with patients already completing their second dose, and preliminary results fully meeting company expectations. Given its broad patient applicability, the therapy’s unique market positioning has attracted strong interest and close attention from multiple global licensing partners.
The World’s Only “No-Screening” Long-Acting Therapy, Addressing Key Competitive Limitations
Based on the latest comparative clinical data, TMB-365/380 demonstrates a clear competitive advantage. A long-acting regimen under development by Gilead—LEN + TAB + ZAB—features dosing once every six months. However, due to sensitivity limitations associated with broadly neutralizing antibodies (bNAbs), patients must pass sensitivity testing for two bNAbs (IC90 ≤ 2 μg/mL), resulting in an exclusion rate of approximately 50% in clinical trials.
In contrast, TaiMed’s TMB-365/380 requires no drug sensitivity testing prior to treatment, making it the only no-screening long-acting therapy currently available worldwide. This enables broader patient coverage and effectively addresses the key limitation faced by competing therapies, where high screening failure rates exclude nearly half of eligible patients.
Strong Clinical Performance and Market Potential
Clinically, Phase 2a Week 24 data showed 0% virologic failure (VF), with 94% of patients maintaining viral loads below 50 copies/mL, demonstrating strong efficacy. The therapy also exhibited an excellent safety profile. Compared to other long-acting treatments such as Cabenuva, which has reported injection-site pain rates of up to 80%, TMB-365/380 showed minimal injection-related discomfort and no serious adverse events.
Targeting the Mainstream Market with Peak Sales Potential of US$3–4 Billion
TaiMed is repositioning TMB-365/380 from a salvage therapy to a first-line maintenance therapy focused on improving quality of life, expanding its target population from approximately 5% of HIV patients to up to 50% of the virologically suppressed population. With Phase 2b enrollment ahead of schedule, the company expects to accelerate global licensing discussions and pursue various strategic partnership opportunities with international pharmaceutical companies.